MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms

MeiraGTx Holdings plc MGTX announced positive clinical data from the ongoing Phase 1 AQUAx study of AAV2-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX), dry mouth symptoms.
Clinically meaningful improvements in xerostomia symptoms were reported consistently across two validated PROs assessing xerostomia symptom severity.
Meaningful increases in whole saliva flow rates were observed post-treatment, providing objective evidence of the biological activity of AAV2-hAQP1 treatment.
Related: MeiraGTx Posts Encouraging Gene Therapy Data From Eye Disorder Trial.
Early long-term follow-up data suggest durability of improvement 2+ years post-treatment.
About 18/24, or 75%, of all unilateral and bilateral treated participants reported symptoms of dry mouth as "better" following treatment.
Each of these 18 participants rated changes in xerostomia scores that were "important" or "very important" (a score of 2 or more).
In the overall cohorts, the average improvement in scores was greater in bilateral than unilateral participants.
Price Action: MGTX shares are down 4.35% at $1.10 on the last check Tuesday.

Momentum86.28

GrowthNot Available

QualityNot Available

Value16.15

Short

Medium

Long